Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Athira Pharma Inc
(NQ:
ATHA
)
3.300
+0.060 (+1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
104,073
Open
3.230
Bid (Size)
3.300 (7)
Ask (Size)
3.320 (10)
Prev. Close
3.240
Today's Range
3.170 - 3.340
52wk Range
1.330 - 4.298
Shares Outstanding
38,054,583
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
August 01, 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Performance
YTD
+14.19%
+14.19%
1 Month
-3.51%
-3.51%
3 Month
+28.91%
+28.91%
6 Month
-17.71%
-17.71%
1 Year
+42.24%
+42.24%
More News
Read More
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
July 09, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
May 29, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
May 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
May 02, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
April 15, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 11, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 27, 2024
Via
Benzinga
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
January 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
January 02, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Sidoti Events, LLC's Virtual December Small-Cap Conference
December 05, 2023
Via
ACCESSWIRE
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
Via
MarketBeat
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
November 29, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.